RxDoctor Payments Data

Om Sharma, MD

Internal Medicine · Englewood, FLNPI 1497798342

Payments from drug & device makers

$2,293in general payments, 2019–2025

Across 69 payments — averaging $33.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$961
  • Lilly USA, LLC$519
  • Pfizer$191
  • Boston Scientific$130
  • Exact Sciences$86
  • Johnson & Johnson$67
  • plus $338 from 14 others

What the payments were for

  • Food & beverage$2,25798%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,293 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$249,263
Medicare patients
611
Services billed
7,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$165,836
XareltoRivaroxaban56$66,001
MounjaroTirzepatide54$54,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$45,096
FarxigaDapagliflozin Propanediol33$44,943
OzempicSemaglutide33$41,360
JardianceEmpagliflozin33$35,051
MultaqDronedarone Hcl19$29,747
Breo ElliptaFluticasone/Vilanterol35$22,877
JanumetSitagliptin Phos/Metformin Hcl13$15,547
VascepaIcosapent Ethyl27$15,485
MyrbetriqMirabegron34$15,303
LinzessLinaclotide18$13,285
Atorvastatin Calcium881$9,709
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$8,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$191$165,836209 claims
GSKTrelegy Ellipta, Breo Ellipta$14$67,97379 claims
Johnson & JohnsonXarelto$67$66,00156 claims
Lilly USA, LLCMounjaro$519$54,97954 claims
AstraZenecaFarxiga$961$44,94333 claims
Boehringer IngelheimJardiance$29$35,05133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Englewood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →